期刊文献+

CyFlow Space流式细胞仪CD34^+细胞绝对计数分析 被引量:4

Research on absolute enumeration of CD34^+ cells detected by CyFlow Space flow cytometry
下载PDF
导出
摘要 目的比较在Partec CyFlow Space流式细胞仪上采用不同设门方法计数CD34+造血干细胞结果的差异。方法采集经骨髓动员的患者外周静脉血标本30例,在分别采用同型对照设门法和国际血液治疗与移植工程协会(ISHAGE)推荐设门法设置流式细胞仪后进行标本测定。结果两种设门法标本计数结果具有相关性(r=0.990),但ISHAGE设门法的计数结果低于同型对照设门法(P<0.05)。回收试验显示,ISHAGE设门法计数不同细胞浓度标本的预期值与回收值的相关系数为0.9989;对3种细胞浓度重复检测的变异系数为2.2%~3.8%。结论两种设门法计数CD34+细胞的相关性较好,但ISHAGE设门法更能反映造血干细胞的特点,具有良好的准确度和精密度,且无需同型对照抗体,节约试剂,更适合临床常规使用。 Objective To compare the difference of CD34^+ cells counts detected by Partec CyFlow Space flow cytometry using two different gating strategies.Methods 30 peripheral blood samples were collected from patients after being treated by bone marrow mobilization,and measured by using ISHAGE gating strategy,recommended by the International Society for Hematotherapy and Graft Engineering,and isotype gating strategy.Results There was fine correlation between the results detected by the two methods(r=0.990),but the detection result of ISHAGE gating was lower than that of isotype gating strategy(P〈0.05).Recovery test indicated that the correlation coefficient between expected and tested value was 0.9989,with the coefficient of variation was 2.2% to 3.8% when three samples with different cell concentration were detected by using ISHAGE gating strategy.Conclusion There could be fine correlation between the results detected by the two gating strategies,but ISHAGE gating strategy is more accurate,with lower cost,and more suitable for clinical laboratory application.
出处 《国际检验医学杂志》 CAS 2011年第13期1471-1473,共3页 International Journal of Laboratory Medicine
关键词 流式细胞术 CD34细胞计数 ISHAGE方案 flow cytometry CD34 absolute counts ISHAGE guidelines
  • 相关文献

参考文献12

  • 1Keeney M,Chin-Yee I,Weir K,et al.Single platform flow cytometric absolute CD34^+ cell counts based on the ISHAGE guidelines[J].Cytometry,1998,34(2):61-70.
  • 2Sutherland DR,Keating A,Nayar R,et al.Sensitive detection and enumeration of CD34^+ cells in peripheral and cord blood by flow cytometry[J].Exp Hematol,1994,22(10):1003-1010.
  • 3Sutherland DR,Anderson L,Keeney M,et al.The ISHAGE guidelines for CD34^+ cell determination by flow cytometry[J].J Hematother,1996,5(3):213-226.
  • 4李山,黄鹏,易珍,李若林,徐明辉,李泰阶,劳小霞,秦雪.同一厂家不同型号血液分析仪检测结果的可比性研究[J].国际检验医学杂志,2009,30(9):833-834. 被引量:17
  • 5刘艳荣,陈珊珊,于弘.流式细胞术计数CD34阳性细胞的标准化与质量控制[J].中国实验血液学杂志,2000,8(4):302-306. 被引量:17
  • 6Brocklebank AM,Sparrow RL.Enumeration of CD34^+ Cells in Cord Blood:a variation on a single platform flow cytometric method based on the ISHAGE gating strategy[J].Cytometry,2001,46(4):254-261.
  • 7Cassens U,Ghde W,Kuling G,et al.Simplified volumetric flow cytometry allows feasible and accurate determination of CD4 T lymphocytes in immunodeficient patients worldwide[J].Antivir Ther,2004,9(3):395-405.
  • 8Pattanapanyasat K,Lerdwana S,Noulsri E,et al.Evaluation of a new single-parameter volumetric flow cytometer(CyFlow green) for enumeration of absolute CD4^+T lymphocytes in human immunodeficiency virus type 1-infected thai patients[J].Clin Diagn Lab Immunol,2005,12(12):1416-1424.
  • 9Fryland M,Chaillet P,Zachariah R,et al.The partec CyFlow counter could provide an option for CD4^+ T-cell monitoring in the context of scaling-up antiretroviral treatment at the district level in Malawi[J].Trans R Soc Trop Med Hyg,2006,100(10):980-985.
  • 10Manasa J,Musabaike H,Masimirembwa C,et al.Evaluation of the Partec Flow Cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe[J].Clin Vaccine Immunol,2007,14(3):293-298.

二级参考文献35

共引文献32

同被引文献35

  • 1周更生,杨洪,袁丹,李平,叶黎,杨胜利,魏东兵,刘红露,余佳,苏玲,梁姝.国产小型化流式细胞仪对HIV感染者CD4^+T淋巴细胞检测性能分析[J].中国艾滋病性病,2020,0(2):125-128. 被引量:2
  • 2陈兵,欧阳建,陈军浩,周敏,汤莹.网织血小板与造血干细胞移植后造血重建的相关性研究[J].江苏医药,2003,29(10):751-752. 被引量:7
  • 3Andy C, Rawstron, Alberto O, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica, 2008,93 (3): 431-438.
  • 4Bayer Garner IB, Sanderson RD, Dhodapkar MV, et al. Syndecan 1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma:shed syndecan 1 accumulates in fibrotic regions[J]. Mod Pathol,2001,14(5) :1052.
  • 5Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purifieation of syndeean-1 malignant plasma cells[J]. J Immunol Methods, 1997,205(1) :73-79.
  • 6Rawstron AC, Davies FE, Das Gupta R, et al. Flow cytometric plasma disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation[J]. Blood, 2002,100 (11) : 3095.
  • 7Terstappen LW, J ohnsen S, Segers Nolten IM, et al. Indentifiea tion and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry[J]. Blood, 1990, 76 (9) : 1739-1745.
  • 8Sahsrs N, Takeshita A, Shigeno K, et al. Clinieopathologieal and prognostic characteristics of CD56-negative multiple myeloma[J]. Br J Haematol,2002,117(4) :882-885.
  • 9Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression[J]. Blood, 2001,98 ( 1 ) : 187-193.
  • 10Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PET- HEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy[J]. J Clin Oncol, 2008,26 (16) : 2737-2744.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部